INDIVIOR PLC

Key metrics

Financial performance

Net profit margin expanded from -4.7% to 16.9% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (513 filings)

Recent press releases

• New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization2026-05-20

  Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.

• Indivior to Participate in Upcoming Investor Conferences2026-05-14

  2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd

• Indivior Announces $175 Million Accelerated Share Repurchase2026-05-04

  Under the ASR agreement, Indivior will make an upfront payment of $175 million to Barclays and expects to receive an initial delivery of 3,717,473 shares promptly following execution. The final number of shares repurchased will be determined based on the volume weighted average price of Indivior’s common stock during the term of the ASR, less a discount. Final settlement is expected to occur no later than the end of June 2026. Indivior does not expect the ASR to impact its previously issued financial guidance.

• Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance2026-04-30

  Q1’26 Total Net Revenue of $317 Million, Up 19% YoY

• Results, Reports & Presentations2026-04-24

  Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Similar companies

The largest companies sharing INDIVIOR PLC's SEC industry classification (pharmaceutical preparations).